BR9907886A - Composto, uso do mesmo, composição farmacêutica, e, processo de tratamento ou profilaxia de doenças inflamatórias, por exemplo asma ou copd. - Google Patents

Composto, uso do mesmo, composição farmacêutica, e, processo de tratamento ou profilaxia de doenças inflamatórias, por exemplo asma ou copd.

Info

Publication number
BR9907886A
BR9907886A BR9907886-4A BR9907886A BR9907886A BR 9907886 A BR9907886 A BR 9907886A BR 9907886 A BR9907886 A BR 9907886A BR 9907886 A BR9907886 A BR 9907886A
Authority
BR
Brazil
Prior art keywords
inflammatory diseases
copd
prophylaxis
compound
pharmaceutical composition
Prior art date
Application number
BR9907886-4A
Other languages
English (en)
Inventor
David Edmund Bays
Chuen Chan
Caroline Mary Cook
Richard Peter Charles Cousins
Brian Cox
Hazel Joan Dyke
Frank Ellis
Joanna Victoria Geden
Stephen Swanson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9907886(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9803169.3A external-priority patent/GB9803169D0/en
Priority claimed from GBGB9813533.8A external-priority patent/GB9813533D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR9907886A publication Critical patent/BR9907886A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSTO, USO DO MESMO, COMPOSIçãO FARMACêUTICA, E, PROCESSO DE TRATAMENTO OU PROFILAXIA DE DOENçAS INFLAMATóRIAS, POR EXEMPLO ASMA OU COPD". é fornecido de acordo com a invenção, novos compostos de fórmula (I) onde R¹, R² e R³ são como descritos no relatório, processos para prepará-los, formulações que os contêm e seu uso em terapia para o tratamento de doenças inflamatórias.
BR9907886-4A 1998-02-14 1999-02-12 Composto, uso do mesmo, composição farmacêutica, e, processo de tratamento ou profilaxia de doenças inflamatórias, por exemplo asma ou copd. BR9907886A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9803169.3A GB9803169D0 (en) 1998-02-14 1998-02-14 Chemical compounds
GBGB9813533.8A GB9813533D0 (en) 1998-06-23 1998-06-23 Chemical compounds
PCT/EP1999/000915 WO1999041267A1 (en) 1998-02-14 1999-02-12 2-(purin-9-yl) -tetrahydrofuran-3, 4-diol derivatives

Publications (1)

Publication Number Publication Date
BR9907886A true BR9907886A (pt) 2000-10-17

Family

ID=26313119

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9907886-4A BR9907886A (pt) 1998-02-14 1999-02-12 Composto, uso do mesmo, composição farmacêutica, e, processo de tratamento ou profilaxia de doenças inflamatórias, por exemplo asma ou copd.

Country Status (32)

Country Link
US (1) US6610665B1 (pt)
EP (1) EP1056759B1 (pt)
JP (1) JP2002503669A (pt)
KR (1) KR20010082512A (pt)
AP (1) AP2000001881A0 (pt)
AR (1) AR017457A1 (pt)
AT (1) ATE223429T1 (pt)
AU (1) AU757156B2 (pt)
BR (1) BR9907886A (pt)
CA (1) CA2319009A1 (pt)
CO (1) CO4990969A1 (pt)
DE (1) DE69902758T2 (pt)
DK (1) DK1056759T3 (pt)
EA (1) EA200000759A1 (pt)
EE (1) EE200000358A (pt)
ES (1) ES2183516T3 (pt)
HK (1) HK1032062A1 (pt)
HR (1) HRP20000538A2 (pt)
HU (1) HUP0100702A3 (pt)
IL (1) IL137402A0 (pt)
IS (1) IS5576A (pt)
MA (1) MA27121A1 (pt)
NO (1) NO20004045L (pt)
NZ (1) NZ505812A (pt)
PE (1) PE20000270A1 (pt)
PL (1) PL342396A1 (pt)
PT (1) PT1056759E (pt)
SK (1) SK12002000A3 (pt)
SV (1) SV1999000016A (pt)
TR (1) TR200002355T2 (pt)
WO (1) WO1999041267A1 (pt)
YU (1) YU50800A (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
YU44900A (sh) * 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
AR017457A1 (es) * 1998-02-14 2001-09-05 Glaxo Group Ltd Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.
AU750462B2 (en) 1998-06-23 2002-07-18 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
GB9930075D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0115178D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Compounds
AU2002362443B2 (en) 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
EP1778712B1 (en) 2004-08-02 2013-01-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
AR058104A1 (es) 2005-10-21 2008-01-23 Novartis Ag Compuestos organicos
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
MX2009004715A (es) 2006-10-30 2009-05-20 Novartis Ag Compuestos heterociclicos como agentes antiinflamatorios.
CA2711637A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
NZ620020A (en) 2009-08-17 2015-06-26 Intellikine Llc Heterocyclic compounds and uses thereof
WO2011020861A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
EA201391230A1 (ru) 2011-02-25 2014-01-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов trk
KR20140077916A (ko) 2011-09-15 2014-06-24 노파르티스 아게 티로신 키나제로서의 6-치환된 3-(퀴놀린-6-일티오)-[1,2,4]트리아졸로[4,3-a]피라딘
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9414193D0 (en) * 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
AR017457A1 (es) * 1998-02-14 2001-09-05 Glaxo Group Ltd Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.
AU750462B2 (en) * 1998-06-23 2002-07-18 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives

Also Published As

Publication number Publication date
CO4990969A1 (es) 2000-12-26
JP2002503669A (ja) 2002-02-05
EP1056759B1 (en) 2002-09-04
TR200002355T2 (tr) 2000-11-21
ES2183516T3 (es) 2003-03-16
EA200000759A1 (ru) 2001-04-23
DE69902758T2 (de) 2003-05-15
PL342396A1 (en) 2001-06-04
DE69902758D1 (de) 2002-10-10
HUP0100702A3 (en) 2003-01-28
IL137402A0 (en) 2001-07-24
SV1999000016A (es) 1999-10-27
AU757156B2 (en) 2003-02-06
EE200000358A (et) 2001-10-15
AR017457A1 (es) 2001-09-05
DK1056759T3 (da) 2003-01-06
HUP0100702A2 (hu) 2002-01-28
US6610665B1 (en) 2003-08-26
PT1056759E (pt) 2003-01-31
ATE223429T1 (de) 2002-09-15
HRP20000538A2 (en) 2000-12-31
AP2000001881A0 (en) 2000-09-30
EP1056759A1 (en) 2000-12-06
AU2623599A (en) 1999-08-30
MA27121A1 (fr) 2005-01-03
HK1032062A1 (en) 2001-07-06
PE20000270A1 (es) 2000-05-20
YU50800A (sh) 2003-04-30
SK12002000A3 (sk) 2001-07-10
NZ505812A (en) 2002-03-01
NO20004045D0 (no) 2000-08-11
KR20010082512A (ko) 2001-08-30
CA2319009A1 (en) 1999-08-19
NO20004045L (no) 2000-08-11
IS5576A (is) 2000-07-25
WO1999041267A1 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
BR9907886A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo de tratamento ou profilaxia de doenças inflamatórias, por exemplo asma ou copd.
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
BR0114321A (pt) Composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar um composto
BR9916282A (pt) Composto, uso de um um composto e método de tratamento
ES2196377T3 (es) Derivados de naftiridina.
BR9806870A (pt) Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, e, uso de um composto e processo para preparar o mesmo.
BR0206435A (pt) Composto, composição farmacêutica, métodos de tratar a angiogênese em um paciente, de tratar distúrbios relacionados com kdr e proliferativos em um mamìfero, uso de um composto, e, processo para preparar compostos
BR0108678A (pt) Novos compostos
BR0113176A (pt) Compostos biciclo-pirazol, composições farmacêuticas compreendendo os compostos, uso dos compostos na fabricação de medicamentos, processos para a preparação dos compostos, coleção quìmica combinatória e métodos para o tratamento de mamìferos incluindo humanos utilizando os compostos
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
BR0108600A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
BR9808953A (pt) Composto, processo para tratar um distúrbio mediado pela ciclooxigenase-2 em um paciente, e, composição farmacêutica
BR9915420A (pt) Composto, composição farmacêutica, métodos de tratar um distúrbio mediado por tnf e por p38 cinase, inflamação e artrite e processo de preparar pirazóis
BR9810592A (pt) Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
BR0208192A (pt) Derivados espirotricìclicos e seu uso como inibidores da fosfodiesterase-7.
BR9507917A (pt) Reagente para preparar um agente radiofarmacêutico agente formador de imagem processo para preparar o mesmo kit para preparar uma preparação farmacêutica uso do reagente agente radioterapêutico composição e agente radiofarmacêutico
BR9811022A (pt) Composto, composição farmacêutica, e, processo para preparação de um composto
BR0312560A (pt) Novas espiropiperidinas ou espiropirrolidinas tricìclicas
BR0208489A (pt) Derivados de n-(arilsulfonil) beta-aminoácidos, comportando um grupo aminoetilado substituìdo, o respectivo processo de preparação e as composições farmacêuticas que os contêm
BR0210464A (pt) Composto, composição farmacêutica, processo para preparar um composto, e, uso de um composto
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007.